QGEN has been the topic of several other research reports. Commerzbank Ag reaffirmed a buy rating on shares of Qiagen NV in a report on Wednesday, January 25th. Deutsche Bank AG reaffirmed a buy rating on shares of Qiagen NV in a report on Monday, January 30th. Zacks Investment Research raised shares of Qiagen NV from a sell rating to a hold rating in a report on Tuesday, March 28th. Barclays PLC reaffirmed a buy rating and issued a $33.00 target price on shares of Qiagen NV in a report on Monday. Finally, Evercore ISI upped their target price on shares of Qiagen NV from $30.00 to $31.50 and gave the stock an outperform rating in a report on Thursday, May 4th. Seven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $28.36.
Qiagen NV (NASDAQ:QGEN) traded up 1.74% on Monday, reaching $32.68. 450,195 shares of the company’s stock were exchanged. The firm has a 50-day moving average of $29.92 and a 200-day moving average of $29.12. The firm has a market capitalization of $7.44 billion, a price-to-earnings ratio of 90.78 and a beta of 1.05. Qiagen NV has a 12 month low of $20.71 and a 12 month high of $32.80.
Several hedge funds have recently made changes to their positions in the stock. FNY Managed Accounts LLC purchased a new stake in shares of Qiagen NV during the first quarter worth $103,000. Oppenheimer Asset Management Inc. purchased a new stake in shares of Qiagen NV during the first quarter worth $114,000. Quadrant Capital Group LLC increased its stake in shares of Qiagen NV by 403.4% in the first quarter. Quadrant Capital Group LLC now owns 5,517 shares of the company’s stock worth $154,000 after buying an additional 4,421 shares in the last quarter. Riverhead Capital Management LLC increased its stake in shares of Qiagen NV by 402.2% in the third quarter. Riverhead Capital Management LLC now owns 5,800 shares of the company’s stock worth $159,000 after buying an additional 4,645 shares in the last quarter. Finally, Elkfork Partners LLC purchased a new stake in shares of Qiagen NV during the fourth quarter worth $180,000. Institutional investors and hedge funds own 60.68% of the company’s stock.
About Qiagen NV
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.